Excellos provides cell therapy contract development and manufacturing services, specializing in the production of autologous and allogeneic CAR-T, TIL, and TCR therapies using a proprietary Excellos 360 platform for deep cell characterization. The company addresses variability in clinical responses by sourcing diverse, high-retention donor cells and ensuring cGMP-compliant manufacturing processes to enhance the success rates of cell therapy trials.
Funding
$20M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cell therapies often exhibit variability in clinical responses due to inconsistencies in starting material and manufacturing processes. This variability can lead to reduced efficacy and increased costs in clinical trials and commercial production. Existing cell and donor screening methods may not provide a comprehensive understanding of the metabolic and effector potential of cells, hindering the development of robust and reliable cell therapies.
Solution
Excellos is a cell therapy contract development and manufacturing organization (CDMO) that addresses variability in cell therapy outcomes by providing comprehensive cell characterization and cGMP-compliant manufacturing services. The company's Excellos 360 platform offers deep immune profiling of donor cells, assessing their metabolic and effector potential beyond traditional surface markers. Excellos sources diverse, high-retention donor cells and utilizes skilled manufacturing processes in ISO 7 cleanrooms to process, transduce, harvest, expand, and cryopreserve cells according to client specifications. This approach aims to reduce variability, improve clinical outcomes, and enhance the success rates of cell therapy programs.
Target Audience
Excellos serves biotechnology and pharmaceutical companies involved in immunotherapy development, including those focused on adoptive cell therapies such as TIL therapy, autologous and allogeneic CAR-T/NK therapies, and TCR therapy.
Features
- Excellos 360 platform for comprehensive immune cell profiling, including assessment of metabolic and effector potential
- Custom-sourced, diverse donor pool with rich diversity in ethnicity, sex, and age
- cGMP production in ISO 7 cleanrooms for cell processing, transduction, expansion, and cryopreservation
- Capabilities for autologous and allogeneic CAR-T, TIL, and TCR therapies
- Donor management services, including donor recruitment and recall
- Assay development and process development services
- Tech transfer services for seamless integration of client processes
- Stability testing and storage services